22308_Navigating the Complexities of Recognizing, Diagnosing and Treating Transthyretin Amyloid Polyneuropathy

In this program, ATTR-PN experts (Chair Dr. Sami Khella, and faculty members Dr. Morie Gertz and Dr. Amanda Peltier) will describe the signs, symptoms, hereditability, and other factors that indicate possible ATTR-PN. The diagnostic process will be explained, and data with currently available and emerging therapies will be discussed.

Transthyretin amyloid polyneuropathy (ATTR-PN) is often unrecognized, misdiagnosed and either inappropriately treated or undertreated owing to the rarity of the disease. There have been substantial advances in the understanding of ATTR-PN which have led to enhanced diagnostic approaches with genetic testing, along with recently approved and emerging targeted treatments. In this program, ATTR-PN experts (chair Dr. Sami Khella, and faculty members Dr. Morie Gertz and Dr. Amanda Peltier) will describe the signs, symptoms, hereditability, and other factors that indicate possible ATTR-PN. The diagnostic process will be explained, and data with currently available and emerging therapies will be discussed.

Login to your Account